Viral Specific T-cells for Treatment of COVID-19

Inclusion Criteria

• •1. Patients who have evidence of infection with SARS-CoV-2
• •2. Patients with symptomatic COVID-19 disease, as defined by at least one of the following
• •1. Imaging (CXR, CT scan, etc.) with pulmonary infiltrates consistent with COVID-19 infection
• •2. Requirement for supplemental oxygenation
• •3. Need for additional respiratory support, including, but not limited to High flow 02, CPAP, BiPAP, Mechanical ventilation
• •3. Age \>1 day
• •4. Clinical status must allow tapering of steroids to \< 0.5mg/kg prednisone or other steroid equivalent
• •5. Have failed at least one FDA-approved treatment for COVID-19 disease
• •6. Must be able to receive VST infusion in Ohio (informed consent obtained by CCHMC PI or sub-investigator either in person or by phone)